Investigational drug · Phase 3
ZN-c3
Also called: azenosertib
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ovarian Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Uterine Serous Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
2 still active
All registered trials
17
Any phase or sponsor naming "ZN-c3"
First trial start
2021
Jul 28, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ZN-c3", any sponsor or status.
- Phase 112
Conditions studied
As listed on its trial records.
- Ovarian Cancer
- High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Uterine Serous Carcinoma
- Platinum-resistant Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
Approved drugs for the same conditions: Ovarian cancer · Oncology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "ZN-c3" as an intervention, largest first.
- A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein ExpressionPivotal-lookingRecruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncIndustry
NCT07546500 · 420 participants (planned) · Start Apr 17, 2026 · Primary completion May 31, 2028
Drug: Investigator's choice of Chemotherapy; Azenosertib · For: Ovarian Cancer
Sites: Phoenix, Arizona; Antioch, California; Beverly Hills, California · 129 sites in all
- A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerPivotal-lookingRecruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncIndustry
NCT05128825 · 310 participants (planned) · Start Feb 17, 2022 · Primary completion Dec 1, 2026
Drug: azenosertib · For: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Sites: Mobile, Alabama; Phoenix, Arizona; Tucson, Arizona · 89 sites in all
- A Study of Azenosertib (ZN-c3) in Participants With Solid TumorsPivotal-lookingCompleted
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncIndustry
NCT04158336 · 274 participants · Start Nov 1, 2019 · Primary completion May 6, 2025
Drug: Azenosertib · For: Solid Tumor
Sites: Tucson, Arizona; Newport Beach, California; Chicago, Illinois · 8 sites in all
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncIndustry
NCT04516447 · 172 participants (planned) · Start Oct 26, 2020 · Primary completion Jun 30, 2028
Drug: Azenosertib; Carboplatin and 4 more · For: Solid Tumor; Epithelial Ovarian Cancer; Fallopian Tube Cancer and 1 more
Sites: Aurora, Colorado; Boston, Massachusetts; St Louis, Missouri · 35 sites in all
- A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerCompleted
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncIndustry
NCT05198804 · 117 participants · Start Jan 27, 2022 · Primary completion Oct 15, 2025
Drug: Azenosertib; Niraparib · For: Ovarian Cancer; Platinum-resistant Ovarian Cancer; Primary Peritoneal Carcinoma and 1 more
Sites: Tucson, Arizona; Aurora, Colorado; Miami Beach, Florida · 22 sites in all
- A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous CarcinomaCompleted
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncIndustry
NCT04814108 · 92 participants · Start Jul 28, 2021 · Primary completion Oct 22, 2025
Drug: Azenosertib · For: Uterine Serous Carcinoma
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 56 sites in all
OHSU Knight Cancer InstituteAcademic, hospital or other
NCT04005690 · 90 participants (planned) · Start Aug 1, 2019 · Primary completion Jun 1, 2027
Drug: Cobimetinib; Olaparib and 4 more · For: Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8 and 5 more
Sites: Portland, Oregon
National Cancer Institute (NCI)NIH
NCT06364410 · 48 participants (planned) · Start Feb 3, 2025 · Primary completion Jul 8, 2027
Drug: Azenosertib; Trastuzumab Deruxtecan · For: Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8 and 10 more
Sites: Houston, Texas
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncIndustry
NCT05743036 · 44 participants · Start Feb 27, 2023 · Primary completion Jul 16, 2024
Drug: ZN-c3; Encorafenib and 1 more · For: Metastatic Colorectal Cancer
Sites: Los Angeles, California; Merriam, Kansas; Houston, Texas · 27 sites in all
K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.Industry
NCT05682170 · 40 participants · Start Dec 1, 2022 · Primary completion Jul 2, 2024
Drug: ZN-d5 ZN-c3; ZN-c3 · For: Acute Myeloid Leukemia (AML)
Sites: Birmingham, Alabama; San Francisco, California; Boston, Massachusetts · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Possibility of Synthetic Lethality: Wee1 Kinase as a Promising Treating Target for Cancer.
Xue X, Chen X, Jiang Y, et al. · Med Res Rev 2026
- Discovery of APO-50815, a potent WEE1 kinase inhibitor with exceptional efficacy against patient-derived colorectal cancer organoids.
Syphers JL, Wright JA, de Nys R, et al. · Eur J Med Chem 2026
- Molecular Response Assessment From Circulating Tumor DNA in Patients With Ovarian Cancer Treated With the WEE1 Inhibitor Azenosertib.
Jeong J, Ma J, Abed M, et al. · JCO Precis Oncol 2026
- WEE1 kinase in cancer: Molecular mechanisms and inhibitor insights.
Kumar A, Paudel KR, Kaur R, et al. · EXCLI J 2026
- The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads.
Guo X, Kim D, Harismendy O, et al. · iScience 2026
- Therapeutic scheduling of WEE1 inhibition preserves T cell function and promotes immune control of HPV+ tumors.
Liu Y, Zhang Z, Tao Y, et al. · bioRxiv 2026
Also in development for Ovarian Cancer
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.